Recently, the investigational new drug （IND） application for HS-20089 （for injection） and HS-20093 （for injection）， two new Class 1 therapeutic biological products independently developed by Shanghai Hansoh BioMedical Co., Ltd. under Hansoh Pharma （3692.HK）， was accepted and publicized by the National Medical Products Administration （NMPA）。

▲ Screenshot of public information from CDE, NMPA